Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Risk of COVID-19 after natural infection or vaccination
the NIAID-funded COVID-19 Prevention Network (CoVPN)
Medicine - Infectious Disease and International Medicine
Pulmonary, Allergy, Critical Care and Sleep Medicine
Administration (TMED)
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Risk of COVID-19 after natural infection or vaccination'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
AstraZeneca
9%
Complete Protection
9%
COVID-19
36%
COVID-19 Risk
100%
COVID-19 Vaccine
9%
CROSS Protocol
9%
Decreased Risk
9%
Efficacy Index
9%
Efficacy Study
9%
Group-based
9%
Hazard Ratio
18%
Hybrid Immunity
54%
Individual Patient Data
9%
Infection Rate
9%
Infection-induced Immunity
27%
Moderna
9%
National Institutes of Health
9%
Natural Infection
100%
Near-complete
9%
Novavax
9%
Placebo
36%
Previous Infection
100%
Protective Efficacy
9%
Protocol Analysis
9%
Quantitative PCR
9%
SARS-CoV-2 Infection
9%
Severe COVID-19
9%
Severe Disease
9%
Statistical Inference
9%
Two-dose Vaccination
9%
US Government
9%
Vaccination
100%
Vaccine Trial
18%
Vaccine Types
9%
Immunology and Microbiology
COVID-19
100%
Hybrid Immunity
40%
Infection
100%
Patient Coding
6%
Reverse Transcription Polymerase Chain Reaction
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Mathematics
Hazard Ratio
100%
Individual Patient
50%
Inferential Statistics
50%
Patient Data
50%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
6%
COVID-19 Vaccine
6%
Diseases
6%
Efficacy Study
6%
Infection
100%
Placebo
26%
SARS Coronavirus
6%